Pre-Market Breakdown: Galena Biopharma Inc., Novavax Inc., Ariad Pharma Inc.,
and MannKind Corp.
LONDON, November 27, 2013
LONDON, November 27, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, November 26, 2013, the U.S. equity market ended on a higher note.
The S&P 500 and the NASDAQ Composite gained 0.01% and 0.58%, respectively,
while the Dow Jones Industrial Average ended flat. Shares in the biotechnology
industry were mostly in the black as the broader market posted gains. The
major movers in the industry included Galena Biopharma Inc. (NASDAQ: GALE),
Novavax Inc. (NASDAQ: NVAX), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and
MannKind Corporation (NASDAQ: MNKD). All these companies are tracked by
AAAResearchReports.com. Free technical research on GALE, NVAX, ARIA, and MNKD
can be downloaded upon signing up at:
On Tuesday, shares in Galena Biopharma Inc. rallied to end the day at $3.88,
which is 5.72% higher than the previous day's closing price of $3.67. The
company's shares vacillated between $3.76 and $4.04 during the trading
session. A total of 6.58 million shares were traded, which is above the daily
average volume of 3.68 million. The company's shares have surged 73.99% in the
last one month and 63.71% in the previous three months, outperforming the S&P
500, which has gained 2.44% and 8.81% during the respective periods. Moreover,
Galena Biopharma Inc.'s stock is trading above its 50-day and 200-day moving
averages of $2.38 and $2.21, respectively. Sign up and read the complimentary
report on GALE at:]
Novavax Inc.'s stock edged higher on Tuesday, tracking gains in the broader
market. The company's shares closed the day 0.58% higher at $3.44, after
trading between $3.38 and $3.47. A total of 2.93 million shares were traded,
which is below the daily average volume of 3.10 million. The company's shares
have gained 19.44% in the last one month and 13.16% in the previous three
months, outperforming the S&P 500, which has advanced 2.44% and 8.81% during
the respective periods. Additionally, Novavax Inc.'s stock is trading above
its 50-day and 200-day moving averages of $3.06 and $2.52, respectively. The
free report on NVAX can be downloaded by signing up now at:
On Tuesday, Ariad Pharmaceuticals Inc.'s stock plummeted to finish at $4.68,
down 8.79% from the prior day's closing price of $5.13. The company's shares
fluctuated between $4.56 and $5.62 during the trading session. A total of
78.75 million shares were traded, which is above the daily average volume of
14.37 million. Despite Tuesday's pullback, the company's shares have rallied
67.74% in the previous three trading sessions and 31.46% in the last one
month, outperforming the S&P 500, which has gained 0.38% and 2.44% during the
respective periods. Furthermore, Ariad Pharmaceuticals Inc.'s stock is trading
below its 50-day and 200-day moving averages of $8.40 and $16.29,
respectively. A free report on ARIA can be accessed by registering at:
Shares in MannKind Corp. oscillated between $4.98 and $5.04 before ending
Tuesday's session 0.60% higher at $5.02. A total of 2.48 million shares were
traded, which is below the daily average volume of 4.97 million. The company's
shares have gained 0.60% in the previous three trading sessions, outperforming
the S&P 500, which has gained 0.38% during the same period. However, MannKind
Corp.'s stock is trading below its 50-day and 200-day moving averages of $5.26
and $5.32, respectively. Register with AAA Research Reports and download
research on MNKD for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.